Last A$0.18 AUD
Change Today 0.00 / 0.00%
Volume 1.6K
PGL On Other Exchanges
As of 10:09 PM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

progen pharmaceuticals ltd (PGL) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/26/14 - A$1.29
52 Week Low
10/13/14 - A$0.16
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

progen pharmaceuticals ltd (PGL) Related Businessweek News

No Related Businessweek News Found

progen pharmaceuticals ltd (PGL) Details

Progen Pharmaceuticals Limited, a biotechnology company, discovers, researches, and develops biopharmaceutical therapeutics for the treatment of human diseases in Australia and the United States. It focuses on the development of the anti-angiogenesis and anti-metastatic oncology products pipeline. The company’s products in research and development stage include PG545, an anti-cancer compound in preclinical development; and PI-88 melanoma program that is in Phase III clinical trial in post-resection liver cancer. It also provides contract services related to the process development, manufacture, and quality assurance of biological products. Progen Pharmaceuticals Limited is based in Darra, Australia.

progen pharmaceuticals ltd (PGL) Top Compensated Officers

General Manager of Finance
Total Annual Compensation: A$104.1K
Chief Executive Officer of Pharmasynth Pty Lt...
Total Annual Compensation: A$146.3K
Company Secretary
Total Annual Compensation: A$45.7K
Director of Business Development & Legal
Total Annual Compensation: A$167.6K
Director of Drug Development
Total Annual Compensation: A$154.3K
Compensation as of Fiscal Year 2014.

progen pharmaceuticals ltd (PGL) Key Developments

Progen Pharmaceuticals Limited Completes Assessment of the Second Patient Cohort in its PG545 Phase 1 Clinical Trial

Progen Pharmaceuticals Limited announced that it has completed assessment of the second patient cohort in its PG545 Phase 1 clinical trial. Progen together with an independent medical monitor and the co-ordinating investigators have reviewed the safety data from this cohort and have agreed to progress to the next dose level of PG545. Each patient in the second cohort received once-weekly 50mg doses of PG545. No dose limiting toxicities were reported from the group following at least four weeks of treatment. Accordingly, the recruitment of the third cohort of three patients has commenced. Each of the patients in the third group will receive 100mg doses of PG545 at once-weekly intervals. The study is entitled an open-label, multi-centre Phase I study of the safety and tolerability of IV infused PG545 in patients with advanced solid tumours". The study is expected to enrol approximately 25 advanced cancer patients. The primary objective of the study is the determination of the maximum tolerated dose (MTD) as defined by significant dose limiting toxicity (DLT). The secondary objectives are: assessment of the safety and tolerability of PG545 following multiple doses in subjects with advanced solid malignancies; to estimate pharmacokinetic parameters of PG545 and explore pharmacokinetic/pharmacodynamic relationships; and to document any anti-tumour activity observed with PG545. The clinical trial is being carried out at three sites in Australia.

Progen Pharmaceuticals Limited Announces Audited Consolidated and Parent Earnings Results for the Year Ended June 30, 2014

Progen Pharmaceuticals Limited announced audited consolidated and parent earnings results for the year ended June 30, 2014. For the year, on consolidated basis, revenue was AUD 5,753,570 against AUD 3,510,103 a year ago. Loss before income tax expense was AUD 1,806,945 against AUD 2,092,134 a year ago. Net loss for year was AUD 1,806,945 against AUD 2,092,134 a year ago. Basic and diluted loss per share was 3.3 cents against 7.5 cents a year ago. Net cash flows from operating activities were AUD 2,498,474 against AUD 2,560,376 a year ago. Purchase of plant and equipment was AUD 467,907 against AUD 49,318 a year ago. For the year, on parent basis, net loss was AUD 1,819,600 against AUD 2,339,807 a year ago.

Progen Pharmaceuticals Limited Announces the Results of the Interim Analysis for the Phase III Patron Clinical Trial for PI-88

Progen Pharmaceuticals Limited announced the results of the interim analysis for the Phase III PATRON clinical trial for PI-88. The company's PI-88 licensee, Medigen Biotechnology Corp. (Medigen") (Taipei, Taiwan), has disclosed the results of the interim analysis of PI-88's Phase III PATRON clinical trial. The PATRON trial is a fully recruited randomised, placebo-controlled Phase III trial being conducted in Taiwan, South Korea, China and Hong Kong to confirm the safety and efficacy of PI-88 in the adjuvant treatment of hepatocellular carcinoma after surgical resection. The interim analysis conducted by an independent committee of medical and statistical experts is based on the results from the first 131 recurrent patients (representing 60% of the total targeted recurrent 218 patients). The results have indicated that PI-88 has a good safety profile, and that based on recurrent data from each individual clinical trial centre, PI-88 did not meet the primary endpoint of Disease Free Survival. Further data analysis by the independent committee will be performed when data from BioClinica, an independent medical imaging company in the US, is available.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGL:AU A$0.18 AUD 0.00

PGL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PGL.
View Industry Companies

Industry Analysis


Industry Average

Valuation PGL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGEN PHARMACEUTICALS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at